Erythropoietin in chronic renal failure

Kidney International

Volumn 50, Issue 4, 1996, Pages 1373-1391

  Valderrâbano, Fernando ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS GLUCONATE; FERROUS SULFATE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; CASE REPORT; CHRONIC KIDNEY FAILURE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029848803     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.452     Document Type: Review

References (169)

1. VALDERRÁBANO F, JONES EHP, MALLICK NP: Report on management of renal failure in Europe. XXIV, 1993. Nephrol Dial Transplant 10 (suppl 10):5-29, 1995
2. WINEARLS CG: Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 10(suppl 2):3-9, 1995
3. MACDOUGALL IC, TUCKER B, THOMPSON J, BAKER LRI, RAINE AGE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. J Am Soc Nephrol 4:428, 1993
4. TEEHAN BP: US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind. placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18:50-59, 1991
5. LIM VS, DEGOWIN RL, ZABALA D, KIRCHNER PT, ABELS R, PERRY P, FANGMAN J: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110:108-114, 1989
6. JACOBS C: Starting r-HuEPO in chronic renal failure: when, why, and how? Nephrol Dial Transplant 10(suppl 2):43-47, 1995
7. KOENE RAP, FRENKEN LAM: Starting r-HuEPO in chronic renal failure: when, why. and how? Nephrol Dial Transplant 10(suppl 2):35-42. 1995
8. MIGUEL JL, TRAVER JA, JOERE RM, LOPEZ JM, OTERO A, ESTEBAN JA, GRANDE J, DIAZ HF, SANCHEZ E, CUBERO JJ, MARTIN J, CHACON JC, RUBIO F: Tratamiento de la anemia de la insuficiencia renal crónica con eritropoyetina humana recombinate (rHu-EPO) en pacientes no dializados. Nefrología 15:148-155, 1995
9. GRANOLLERAS C, BRANGER B, BEAU MC, DESCHODT G, ALSABADANI B, SHALDON S: Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol 76:143-148, 1989
10. ANASTASSIADES E, HOWART D, HOWART JE: Influence of azathioprinc on the ferrokinetics of patients with renal failure before and after treatment with erythropoietin. Nephron 67:291-296, 1994
11. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
12. GARCIA DL, ANDERSON S, RENNKE HG, BRENNER BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85:6142-6146, 1988
13. RUEDIN P, LEMOINE R, BOEUIILE M, LI SKI M, KAUEER A: Prevention of accelerated progression of renal failure induced by recombinant human erythropoietin in the rat remnant kidney (abstract). Nephrol Dial Transplant 6:828, 1991
14. ONAYAMA K: Effects of human recombinant erythropoietin on anemia, systemic hemodynamics and renal failure in predialysis patients. Nephrol Dial Transplant 4:966-970, 1989
15. ABRAHAM PA, OPSAHL JA, RACHAEL KA, ASINGER R, HALSTENSON CE. Renal function during erythiopoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990
16. LIM VS, FRANGMEN J, FLANIGAN MJ, DEGOWIN RL, ABELS RT: Fffects of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990
17. ROTH D, SMITH RD, SCHULMAN G, BENZ RL, TEEHAM BP, ET AL: effects of r-HuEPO on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
18. LOPEZ-GOMEZ JM, JOFRE R, MORENO F, VERDE E, VALDERRÁBANO F: R-HuEPO in pre-dialysis and in dialyzed patients. Nephrol Dial Transplant 10(suppl 6):31-35, 1995
19. LEVEY AS: Nephrology Forum: Measurement of renal function in chronic renal disease. Kidney Int 38:167-184, 1990
20. KÜHN K. NONNAST-DANIEL B, GRÜTZMACER P, GRÜNER J, PFAFF W, BALDAMUS CA, SCIGALLA P: Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Contrib Nephrol (Basel) 66:94-103, 1998
21. STIVELMAN JC: Resistance to recombinant human erythropoictin therapy: a real clinical entity? Semin Nephrol 9(suppl 2):8-11, 1989
22. VAN WYCK DB, STIVELMAN JC, RUIZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoielin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
23. KOOISTRA MP, VAN Es A, STRUYVENBERG A, MARX JJ: Iron metabolism in patients with anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991
24. ANASTASSIADES EG, HOWARTH D, HOWARTH J, SHANKS D, WATERS HM, HYDE K, GEARY CG, LIU YIN JA, GOKAI. R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
25. BEGUIN Y, LOO M, R'ZIK S, SAUTOIS B, LEJEUNE F, RORIVE G, FILLET G: Early prediction of response of recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogon. Blood 82:2010-2016, 1993
26. MACDOUGALL IC, CAVILL I, HULME B, BAIN B, MCGREGOR E, MCKAY P, SANDERS E, COLES GA, WILLIAMS JD: Detection of functional iron deficiency during erythopoietin treatment: a new approach. Br Med J 304:225-226, 1992
27. DANIELSON B: R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 10(suppl 2):69-73, 1995
28. DRÜEKE TB: R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 10(suppl 2):62-68, 1945
29. RAO DS, SHIH MS, MOHINI R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328;171-175, 1993
30. GOICOECHEA M, GOMEZ-CAMPDERA F, POLO JR, TEJEDOR A, RUIZ MA, VAZQUEZ I, VERDE E, VALDERRÁBANO F: Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. Clin Nephrol, 45:420-421, 1996
31. MEYTFS D, BOFIN E, MA A, DUKES PP, MASSRY SG: Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67:1263-1269, 1981
32. DOLWICHE F, GARRITY MJ, POWELL JS, ROBERTSON RP, ADAMSON JW: High levels of the circulating form of parathyroid hormone do not inhibit in vitro erythropoiesis. J Lab Clin Med 102:613-620, 1983
33. MCGONIGLF RJS, WALLIN JD, HUSSERI F, DEFTOS LJ, RICE JC, O'NEILL WJ, FISHER JW: Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med 104:1016-1020, 1984
34. CANNATA JB, FERNANDEZ-SOTO I, FERNANDEZ-MENENDEZ MJ, FERNANDEZ-MARTIN JL, MCGREGOR SJ, BROCK JH, HALLS D: Role of iron metabolism in absorption and cellular uptake of aluminium. Kidney Int 39:794-803, 1991
35. CANNATA JB, GOMEZ AC, FERNANDEZ MMJ, FERNANDEZ SI, MACGREGOR S, MENEDEZ-FRAGA P, BROCK JH: Iron uptake in aluminum overload: in vivo and in vitro studies. Nephrol Dial Transplant 6:637-642, 1991
36. DE BROE ME, DRÜEKE TB, BITZ E: Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 8(suppl 1):1-4, 1993
37. ROGER SD, STEWART JH, HARRIS DCH: Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. Nephron 58:33-36, 1999
38. ESCHBACH JW: Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 9:203-209, 1988
39. SMTIH MA, KNIGHT SM, MADISON PJ, SMITH JG: Anemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Ann Rheum Dis 51:753-757, 1992
40. HEBERT LA, BIRMINGHAM DJ, SHEN XP: Effect of recombinant human erythropoietin therapy on autoimmunity in systemic lupus erythematosus. Am J Kidney Dis 24:25-32, 1994
41. HORINA JA, PETRITSCH W, SCHMID CR, REICHT G, WENZL H, SILLY H, KREJS GJ: Treatment of anemia in inflammatory bowel disease with recombinant human erythropoetin: results in three patients. Gastroenterologe 104:1828-1831, 1993
42. MILLER CB, JONES RJ, PIANDATOSI S, AVELOFF MG, SPIVAK JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990
43. JOHNSON RA, COOK CA, FURMANSKI P: In vivo suppression of erythropoiesis by tumor necrosis factor alpha (TNF-α): reversal with exogenous erythropoietin. Exp HemaTol 18:109-115, 1990
44. SCHOOLEY JC, KULLGREN B, ALLISON AC: Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 67:11-17, 1987
45. MACDOUGALL IC, ALLEN DA, CAVILL I, BAKER LRI, RAINE AEG: Poor response to erythropoietin in inflammatory conditions may be mediated by interleukin-6 (abstract). Nephrol Dial Transplant 9:1033, 1994
46. MACDOUGALL IC: Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995
47. LOPEZ-GOMEZ JM, GONZALEZ C, LUNO J, ALLES A, RESANO M, JUNCO E, VALDERRABÁNO F: Asociación entre hepatopatia y mejoria de la anemia de pacientes en hemodiálisis periódicas. Nefrología 2:35-38, 1982
48. KLASSEN DK, SPIVAK JL: Hepatitis-related hepatic erythropoietin production. Am J Med 89:684-686, 1990
49. BESADA E, SANZ MORENO C, GARRANCHO JM, SANCHEZ B, BOTELLA J: Erythropoietin response in haemodialysis patient carriers of anti hepatitis C antibodies (abstract). Nephrol Dial Transplant 9:1028, 1994
50. NAVARRO JF, TERUEL JL, VILLAFRUELA JJ, ORTUN̄O J: Hepatitis associated improvement of anaemia in an anephric patient without elevation of serum erythropoietin level. Nephron 65:495-496, 1993
51. FISCHL M, GALPIN JE, LEVINE JD, GROOPMAN JE, HENRY DH, KENNEDY P, MILES S, ROBBINS W, STARRETT B, ZALUSKY R, ABELS RI, TSAI HC, RUDNICE SA: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322:1488-1493, 1990
52. ALMOND MK, TAILOR D, MARSH FP, RAFTERY MJ, CUNNINGHAM J: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9:270-273, 1994
53. PAGE B, ZITOUNI Z, ZINGRAFF J: Resistance to rHuEPO and kidney graft rejection in patients on haemodialysis. Nephrol Dial Transplant 9:961, 1994
54. ALMOND MK, TAILOR D, KELSEY S, CUNNINGHAM J: Treatment of erythropoietin resistance with cyclosporin. Lancet 343:916-917, 1994
55. RUEDIN P, PECHERE-BERTSCHI A, CHAPUIS B, BENEDET P, LESKI M: Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysis patients. Nephrol Dial Transplant 8:315-318, 1993
56. CAILLETTE A, BARRETO S, GIMENEZ E, ET AL: Is erythropoietin treatment safe and effective in myeloma patients receiving haemodialysis? Clin Nephrol 40:176-178, 1993
57. CHENG IKP, LU HB, WEI DCC, CHENG SW, CHAN CY, LEE FDP: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142-148, 1993
58. RODGERS GP, DONER GJ, UYESAKA N, NOGUCHI CT, SCHECHTER AN, NIENHUIS AW: Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73-80, 1993
59. BOWEN D, CULLIGAN D, JACOBS A: The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77:419-423, 1991
60. MAIER RF, OBLADE M, SCIGALLA P: The effect of epoietin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med 330:1173-1178, 1994
61. GASTALDELLO K, VEREERSTRAETEN H, NZAME-NZE T, VANHERWEGHEM JL, TIELMANS C: Resistance to erythropoietin in iron overload haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10(suppl 6):44-47, 1995
62. ESCHBACH JW: Nephrology Forum: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant human erythropoietin. Kidney Int 35:134-148, 1989
63. VANUCCI AM, GROSSI A, RAFANELLI D, STATELLO M, GUIDI S, SACCARDI R, ROSSI-FERRINI P: Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 82:978-984, 1993
64. VANUCCI AM, GROSSI A, RAFANELLI D, GUIDI S, SACCARDI R, ALTERINI R, ROSSI-FERRINI P: Impaired erythropoietin production in mice treated with cyclosporin A. Blood 78:1615-1618, 1991
65. NIELSEN OJ, MANDRUP-POULSEN T, NERUP J, CANADIAN-EUROPEAN RANDOMIZED CONTROL TRIAL GROUP: Deficiency of erythropoietin is not responsible for the anemia associated with cyclosporin treatment of insulin-dependent diabetes mellitus. J Intern Med 233:471-476, 1993
66. KAMPER AL, NIELSEN OJ: Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50:611-618, 1990
67. WALTER J: Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 8:1428, 1993
68. VLAHAKOS DV, CANZANELLO VJ, MADAIO MP, MADIAS NE: Enalapril-associated anemia in renal transplant recipients tested for hypertension. Am J Kidney Dis 17:199-205, 1991
69. SANCHEZ-TOMERO JA: ACE inhibitors do not decrease rHuEpo response in patients with end-stage renal disease. Nephrol Dial Transplant 10:1476-1477, 1995
70. BAKRIS GL, SAUTER ER, HUSSEY JL: Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 323:86-90, 1990
71. FINOCCHIARO P, ENIA G, ZOCCALI C: Erythropoietin in primary oxalosis. J Nephrol 4:249-250, 1991
72. ESCHBACH JW: The future of r-HuEPO. Nephrol Dial Transplant 10(suppl 2):96-109, 1995
73. PERTOSA G, TARANTINO EA, GESUALDO L, MONTINARO V, SCHENA FP: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 43(suppl 41):S221-S225, 1993
74. PEREZ-GARCIA R, ANAYA F, CHISVERT J, VALDERRÁBANO F: Association of high-flux dialyzers and bacterial contamination of dialysate-induced chronic release of cytokines in haemodialysis patients. Nephrol Dial Transplant 10:2164-2166, 1995
75. HÖRL WH: How to get the best out of r-HuEPO. Nephrol Dial Transplant 10(suppl 2):92-95, 1995
76. KONIJN AM, HERSHKO C: Ferritin synthesis in inflammation: pathogenesis of impaired iron release. Br J Haematol 37:7-16, 1977
77. SCHAEFER RM, SCHAEFER L, HEIDLAND A: The hypochromic red cell, a new parameter for the monitoring of iron therapy during rHuEPO treatment. Clin Invest 72:1310, 1994
78. BRUNATTI C, PIPERNO A, GUASTONI C, PERRINO ML, CIVATI G, TEATINI U, PEREGO A, FIORELLI G, MINETTI L: Erythrocyte ferritin in patients on chronic hemodialysis treatment. Nephron 54:209-213, 1990
79. AHMED Y, FADIA A, BASKIN S, LASKER N: What is the best laboratory indicator for iron availability in hemodialysis patients? J Am Soc Nephrol 4:423, 1993
80. PIAZZA V, VILLA G, GALLI F, SEGAGNI S, BOVIO G, POGGIO F, PICARDI L, SALVADEO A: Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis. Nephron 61:54-57, 1992
81. DEMARCHI S, CECCHIN E: Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. Clin Sci 81:113-121, 1991
82. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE, LEDINGHAM JGG, OLIVER DO: Iron metabolism in haemodialysis patients. Q J Med 48:369-391, 1979
83. SKIKNE BS, COOK JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Invest 5:746-751, 1992
84. DONELLI SM, POSEN GA, ALI MAM: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991
85. LAI KN, LUI SF, LEUNG, JCK, LAW E, NICHOLLS MG: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57:394-400, 1991
86. HÖRI, WH: Subcutaneous erythropoietin. Acta Haematol 87(suppl 1):16-19, 1992
87. ASHAI NI, PAGANINI EP, WILSON JM: Intravenous versus subcutaneous dosing of epoietin: a review of the literature. Am J Kidney Dis 22(suppl 1):23-31, 1993
88. TAYLOR JE, BELCH JJE, FLLMING LW, MACTIER RA, HENDERSON IS, STEWART WK: Erythropoietin response and route of administration. Clin Nephrol 41:297-302, 1994
89. SUNDER-PLASSMANN G, HÖRI, WH: Optimizing low dose r-HuEPO combined with low dose i.v. iron therapy in hemodialysis patients. J Am Soc Nephrol 5:478, 1994
90. MACDOUGALL IC, JONES JM, ROBINSON MI, MILES JB, COLES GA, WILLIAMS JD: Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 88:152-156, 1991
91. LAGO M, PEREZ-GARCIA R, GARCIA DE VINUESA MS, ANAYA F, VALDERRABÁNO F: Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in haemodialysis patients. Nephron 72:723-724, 1996
92. LUI SF, LAW CB, TING SM, LI P, LAI KN: Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 36:246-251, 1991
93. BALLAL SH, DOMOTO DT, POLACK DC, MARAULONIS P, MARTIN KJ: Androgens potentiate the effect of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidny Dis 17:29-33, 1991
94. BERNS JS, RUDNICK MR, COHEN RM: A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anaemia in patients on chronic haemodialysis. Clin Nephrol 37:264-267, 1992
95. MACDOUGALL IC, ALLEN DA, CAVILL I, BAKER LRI, RAINE AGE: Modulation of erythropoietin action on cytokines in a uremic anemic animal model. J Am Soc Nephrol 5:463, 1994
96. KOOISTRA MP, STRYVENBERG A, VAN Es LA: The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum ereatinine levels. Nephron 57:127-128, 1991
97. RAIOLA P, MANZO M, SAGGESSE A, TOMASINO G, CICHELLA T, RAMBALDI M, PISANO M, LIZZA B, PERNA AF: Treatment of anaemia resistant to conventional erythropoietin therapy with thymopentin in hemodialysis patients. Nephrol Dial Transplant 10(suppl 6):48-50, 1995
98. GEERLINGS W. MORRIS RW, BRÜNNER FP. BRYNGER H, EHRICH JHH, FASSBINDER W, RIZZONI G, SELWOOD NH, TUFVESON G, WING AJ: Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplant 8:585-589, 1993
99. GOLDBERG AP, GELTMAN EM, HACGBERG JM, GAVIN JR, DELMEZ JA, CARNEY RM, NAUMOWICZ A, OLDFIED MH, HARTER HR: Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int 24(suppl 16):S303-S309, 1983
100. METRA M, CANNELLA G, LACNNA G, GUAINI T, SANDRINI M, GAGGIOTTI M, MOVILLI L, DEICAS L: Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am J Cardiol 68:1060-1066, 1991
101. BOOTH FW, THOMASON DB: Molecular and cellular adaptation of muscle in response to exercise: perspectives and various models. Physiol Rev 71:541-585, 1991
102. BAK JF, SCHMITZ O, SORENSSEN SS, FROJKAFR J, KJAER T, PEDERSEN O: Activity of insulin receptor kinase and glycogen synthase in skeletal muscle from patients with chronic renal failure. Acta Endocrinol 121:744-750, 1989
103. BÁRÁNY P, WIBOM R, HULTMAN H, BERGSTRÖM J: ATP production in isolated muscle mitrochondria from hemodialysis patients: effect of correction of anemia with erythropoielin. Clin Sci 81:645-653, 1991
104. EKBLOM B, BERGLUND B: Effect of erythropoietin administration on maximal aerobic power. Scan J Med Sci Sports 1:88-93, 1991
105. BÁRÁNY P, FREYSCHUSS U, PETERSSON E, BERGSTRÖM J: Treatment of anaemia in hemodialysis patients with erythropoietin: long term effects on exercise capacity. Clin Sci 84:441-447, 1993
106. WALLS J: Haemoglobin - is more better? Nephorl Dial Transplant 10(suppl 2):56-61, 1995
107. MUIRHEAD N: Erythropoietin is a cause of access thrombosis. Semin Dial 6:184-188, 1993
108. ESCHBACH JW: Erythropoietin is not a cause of access thrombosis. Simin Dial 6:180-184, 1993
109. GRIMM G, STOCKENHUBER F, SCHNEEWEISS B, MADI C, ZETTLHFER J, SCHNEIDER B: Improvement of brain function in hemodialysis patients treated with crythropoietin. Kidney Int 38:480-486, 1990
110. SCHAEFER RM, KOKOT F, HEIDLAND A: Impact of rcecombinant human erythropoietin on sexual function in haemodialysis patients. Contrib Nephorl (Basel) 76:273-282, 1989
111. KOKOT WIECEK A, GRZESZCZAK W, KLEPACKA J, KLIN M, LAO M: Influence of erythropoietin treatment on endocrine abnormalities in haemodialysis patients. Contrib Nephorl (Basel) 76:257-272, 1989
112. POLLOCK CA, WYNDHAM R, COLLETT PV, ELDER G, FIELD MJ, KALOWSKI S, LAWRENCE JR, WAUGH DA, GEORGE CRP: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 45:497-902, 1994
113. GRIMM PC, SEKIYA NM, ROBERTSON BJ, ETTENGER RB: Recombinant human erythropoietin decreases anti-HLA sensitization and may improve allograft outcome: involvement of antiidiotypic antibody. Transplant proc 23:407-408, 1991
114. PERTZ-GARCIA R, ANAYA F, GARCIA DE VINUESA MS, GOMEZ-CAMPDERA F, GOICOECHEA M, MORENO M, VALDERRÁBANO F: Evolución de la tasa de anticuerpos linfoeitotóxicos en pacientes en diálisis en tratamiento con eritropoyelina. Nefrologia 14:333-340, 1994
115. BÁRÁNY P, PETTERSSON E, AHLBBERG M, HULTMAN E, BERGSTRÖM J: Nutritional assessment in anaemic haemodialysis patients treated with recombinant human erythropoietin. Clin Nephorl 35:270-279, 1991
116. DE MARCHI S, CECCHIN E, VILLALTA D, SEPIACCI G, SANHNI G, BARTOLI E: Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326:969-974, 1992
117. MATSUI C, IDA M, HAMADA M, MOROIHASHI M, HASI GAWA M: Effects of azelastin on pruritus and plasma histamine levels in hemodialysis patients. Int J Dermatol 33:868-871, 1994
118. SILBERBERG JS, BARRE PE, PRICTIARD SS, SNIDERMAN SD: Impact of left ventricular hypertrophy on end-stage renal disease. Kidney Int 36:286-290, 1989
119. PASCUAL J, TFRUFI JL, MOJA JL, JL, LIAN̄ONO F, JIMENEZ MENA M, ORTUN̄O J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study, Clin Nephrol 35:280-287, 1991
120. ZEHNDER C, ZUBER M, SULZER M, MEYER B, STRAUMANN E, JENZER HR, BLUMBERG A: Influence of long term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61:21-25, 1992
121. MANN JFE: Hypertension and eardiovascular effects - long-term safety and potential long-term benefits of rHu-EPO. Nephorl Dial Transplant 10(suppl 2):80-84, 1995
122. ECSHRACH JW, AOUILING T, HALEY NR, FAN MH, BLAGG CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system, Clin Nephrol 38(suppl 1):S98-S103, 1992
123. FEILNER SK, LANG MR, NEUMANN A, KORKARZ C, BOROW KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. kidney Int 44:1309-1315, 1993
124. MARTINEZ-VEA A, VARDAJI A, GARCIA C, RIDAO C, RICHAKT C, OLIVER JA: Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidny Dis 19:353-357, 1992
125. MACDOUGALL IC, LEWIS NP, SAUNDERS MJ, COCHLIN DL, DAVIES ME, HUTTON RD, FOX KAA, COLES GA, WILLIAMS JD: Long term cardiorespiratory effects of amelioration of anemia by erythropoietin. Lancent 335:489-493, 1990
126. TAGAWA N, NAGANO F, SATTO H, UMEZU M, YAMAKADO M: Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin. Proposal for the hematocrit most beneficial to hemodynamics. Clin Nephrol 35:35-38, 1991
127. LONDON G, ZINS B, PANNIER B, NARET C, BERTHELOT JM, JACOUOT C, SAFAR M, DRÜEKE TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878-882, 1989
128. MAYER G, STEFFNELLI TH, CADA EM, THUM J, STUMMVOLL HK, GRAF H: Blood viscosity and hemodynamic parameters in dialysis patients treated with human recombinant erythropoietin. Lancet 1:351-352, 1988
129. MULLER R, STEFFEN HM, BRUNNER R, SARIC J, POLLOK M, BALDAMUS CA, KAUFMANN W: Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin therapy for renal anemia. Clin Invest Med 14:614-622, 1991
130. SCHIFFL H: Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin. Int J Artif Organs 15:343-348, 1992
131. CARLINI RG, RUSSO AS, OBIALO CI, ALVAREZ UM, ROTHSTEIN M: Recombinant human erythropoietin increases endothelin-1 release by endothelial cells. Kidney Int 43:1010-1014, 1993
132. CASATI S, CAMPISE M, CREPALDI M, LOBO J, GRAZIANI G, PONTICELLI C: Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin. Nephrol Dial Transplant 4:718-720, 1989
133. NEVES PL, BERNARDO I, ANUSCIADA AI, AMORIM JP: Correction of intradialysis hypotension: role of bicarbonate dialysis and erythropoietin use. Nephrol Dial Transplant 9:112, 1994
134. SUWATA J, MAEDA H, OHMON N, OHWA M, OHTSUKA H, SHIMOYAMA H: Recombinant human erythropoietin therapy and autonomic nervous system. Nephron 61:115-116, 1992
135. SUNDAL E, KAESER U: Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European Multicentre Study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 4:979-987, 1989
136. CARAVACA F, PIZARRO JL, ARROBAS M, CUBERO JJ, GARCÍA MC, PEREZ MIRANDA M: Anti-platelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney 45:845-851, 1994
137. CANADIAN ERYTHROPOIETIN STUDY GROUP: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 300:573-578, 1990
138. MCMAHON LP, DAWBORN JK: Changes in quality of life at comparative levels of hemoglobin after long-term treatment with erythropoietin. Am J Nephrol 12:358-362, 1992
139. EVANS RW, RADER B, MANNINEN DL: The quality of life of hemodialysis patients treated with recombinant human erythropoietin. JAMA 262:825-830, 1990
140. MORLNO F, ARACIL FJ, PEREZ R, VALDERRÁBANO F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting ESRD-related anemia with erythropoietin. Am J Kidney Dis 27:548-556, 1996
141. KARNOFSKY DA, BURCHENAL JH: The clinical evaluation of chemotherapeutic agents in cancer, in Evaluation of Chemotherapeutic Agents, edited by MALEOD CM, New York, Columbia University Press, 1949, pp 191-205
142. BERGNER M, BOBBITT RA, CARTER WB, GILSON BS: The Sickness Impact Profile: Development and final revision of health-status measure. Med Care 19:787-805, 1981
143. HENDRICSON WD, RUSSELL IJ, PRIHODA THJ, JACOBSON JM, ROGAN A, BISHOP GD: An approach to developing a valid Spanish language translation of a health-status questionnaire. Med Care 27:959-966, 1989
144. FRIMDMAN EA: Diabetic nephropathy, in Therapy of Renal Diseases and Related Disorders (2nd ed), edited by SUKI WN, MASSRY SG, Kluwer, 1991, pp 534-542
145. MORENO F, LOPEZ GOMEZ JM, SANZ GUAJARDO D, JOFRE R, VALDERRÁBANO F: Quality of life in dialysis patients. A Spanish multicentre study. Nephrol Dial Transplant 11 (Suppl 2): 125-129, 1996
146. MORENO F, ARACIL J, PEREZ R, VALDERRÁBANO F: Improvement in the quality of life of haemodialysis patients treated with erythropoietin. A controlled study (abstract). Nephrol Dial Transplant 7:770, 1992
147. VALDERRÁBANO F, MORENO F, ARACIL FJ: A controlled study on the effect of erythropoietin on the quality of life of elderly hemodialysis patients (abstract). J Am Soc Nephrol 3:432, 1992
148. MORENO F, VALDERRÁBANO F, ARACIL FJ, PEREZ R: Influence of hematocrit on quality of life of hemodialysis patients. Nephrol Dial Transplant 4:1034, 1994
149. HIRAKATA H, KANAI H, OKUDA S, FUJISHIMA M: Optimal hematocrit for the maximum oxygen supply to the brain with erythropoietin treatment in hemodialysis patients. J Am Soc Nephrol 5:453, 1994
150. ESCHBACH JW, GLENNY R, ROBERTSON T, GUTHRIE M, RADER B, EVANS R, CHANDLER W, DAVIDSON R, EASTERLINC T, DENNEY J, SCHNEIDER G: Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe (abstract). J Am Soc Nephrol 4:425, 1993
151. HARMETT JB, KENT GM, FOLEY RN, PARFREY PS: Cardiac function and hematocrit level. Am J Kidney Dis 25:(suppl 1):S3-S7, 1995
152. HARMETT JB, MURPHY B, COLLINGWOOD P, PURCHASE L, KENT G, PARFREY PS: The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 65:212-214, 1993
153. RITZ E, ZEIER M, SCHNEIDER P, JONLS E: Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? Nephron 66:125-128, 1994
154. PAGANINI EP: Adapting the dialysis unit to increased hematocrit levels. Am J Kidney Did25(suppl 1):S12-S17, 1995
155. DAHLOF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 5:95-110, 1942
156. MYERS MG: Trough to peak ratio and 24-hour blood pressure control. Am J Hypertens 8:214-219, 1995
157. SILVERBERG DS, IAIWA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
158. BOMMER J, RITZ E, WLINREICH T, BOMMER G, ZEIGLER T: Subcutaneous erythropoietin. Lancet 2:406, 1988
159. WIECEK A, KOKOT F, MARCINKOWSKI W: Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment. Nephorn 69:489-490, 1995
160. HOELDTKE RD, STREETEN DHP, PHIL D: Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 329:611-615, 1993
161. ONOYAMA K, OSATO S, FUJISHIMA M: Haemodynamic effect of recombinant human erythropoietin on anaemic haemodialysis patients. Nephrol Dial Transplant 6:562-565, 1991
162. CARAVACA F, VAGACE JM, APARICIO A, GROISS J, PIZARRO JL, ALONSO N, GARCIA MC, ARROBAS M, CUBERO J, ESPARRAGO J, SANCHEZ-CASADO E: Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy. Am J Kidney Dis 20(3):249-254, 1992
163. TAMG DC, CHEN TW, HUANG TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
164. ALI M, FAYEMI AO, FRANSCINO J, RIGOLOSO R, BRAUN EV, SINGER R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1:652-655, 1982
165. ECSHBACH JW, COOK JD, SCRIBNLR BH, FINCH CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977
166. BASKIN S, LASKER N: Erythropoietin associated hypertension. N Engl J Med 323:999, 1990
167. PAGEL H, JELKMANN W, WEISS C: Erythropoietin and blood pressure. Horm Metab Res 21:224, 1989
168. HEIDENREICH S, RAHN KH, ZIDEK W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39:259-265, 1991
169. ROGER SD, GRASTY MS, BAKER LRI, RAINE AEG: Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. Kidney Int 42:975-980, 1992